Clicky

OCUPHIRE PHARMA DL-0001(R3X1)

Description: Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.


Keywords: Diabetic Retinopathy Blindness Retina Retinopathy Presbyopia Ophthalmic Biopharmaceutical Apx3330 Mydriasis Phentolamine Phentolamine Ophthalmic Phentolamine Ophthalmic Solution Refractive And Retinal Eye Disorders

Home Page: opusgtx.com

37000 Grand River Avenue
Farmington Hills, MI 48335
United States
Phone: 248 957 9024


Officers

Name Title
Mr. George Magrath M.B.A., M.D., M.S. CEO & Director
Mr. Bernhard Hoffmann M.B.A. Senior Vice President of Corporate Development & Secretary
Dr. Jay S. Pepose M.D., Ph.D. Chief Medical Advisor
Ms. Amy Zaremba Rabourn C.P.A., MAcc Senior Vice President of Finance
Mr. Nirav Suresh Jhaveri C.F.A. Chief Financial Officer
Mr. Joseph K. Schachle MBA Chief Operating Officer
Dr. Ashwath Jayagopal Ph.D. Chief Scientific & Development Officer
Ms. Bindu Manne Head of Market Development & Commercialization
Mr. Erik Sims Director & Corporate Controller

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 12.0919
Trailing PE: 0
Price-to-Book MRQ: 1.0132
Price-to-Sales TTM: 4.0848
IPO Date:
Fiscal Year End: December
Full Time Employees: 14
Back to stocks